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1. Introduction
Pulmonary hypertension (PH) is a devastating and potentially life-threatening condition that
results from a heterogeneous group of diseases. PH is characterized by a sustained increase of
mean pulmonary artery pressure (PAP) of 25 mmHg or greater due to any etiology [1]. PH is
the manifestation of abnormal pulmonary vascular bed anatomy, abnormal vasoconstrictive
status, and pulmonary parenchymal abnormalities which result in obstruction to pulmonary
blood flow, cardiac diseases which may impede venous return from the lungs, or a combina‐
tion of the above. Although many different causes exist, hypertension in the pulmonary
circulation is the result of increased vascular resistance, increased vascular bed flow, or a
coexistence of both. Initially the signs and symptoms of PH are usually subtle and nonspecific,
often ignored by the patients. If left untreated, however, these patients with PH will develop
progressive symptoms of dyspnea, fatigue, poor exercise tolerance and right heart failure
culminating in a markedly shortened survival [2]. The mechanism for the pathogenesis of
pulmonary arterial hypertension (PAH) is not completely understood. There is a conceptual
transition in recent decades from the traditional view of mechanical obstruction of blood flow
leading to elevated pressure in the pulmonary circulation to cellular growth and vascular
remodeling causing increased resistance in pulmonary vasculature resistance [3][4]. Though
uncommon, there are patients with PH scheduled for various surgical procedures and
requiring anesthetic care perioperatively. In recent years some emerging strategies in the
management of PH are potentially applicable to anesthesia practice intraoperatively. From the
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clinical anesthesia standpoint, although mild or transient PH won’t considerably complicate
anesthetic management, moderate or severe PH surely can dramatically deteriorate intrao‐
peratively or postoperatively and potentially lead to acute right heart failure (RHF), cardio‐
genic shock and even death. The perioperative management of patients with PH varies
depending upon the pathological features present, functional clinical classification, hemody‐
namic status, and success of current medical therapy. This chapter will review the epidemi‐
ology, etiologies, the mechanisms, especially cellular growth-related remodeling mechanisms,
preoperative evaluation, intraoperative considerations and anesthetic management strategies,
and postoperative management of patients with PH.
2. Definition and classifications of pulmonary hypertension
During the 4th World Symposium on Pulmonary Hypertension held in Dana Point, California
in 2008, the thresholds for the diagnosis of PH were introduced: an mPAP ≥ 25 mm Hg was
designated as manifest PH, while mPAP < 21 mm Hg was defined as normal, and mPAP from
21 to 25 mmHg was categorized as borderline. Correspondingly, echocardiographic systolic
tricuspid regurgitation (TR) velocity thresholds < 2.5 m/s is defined as normal, 2.5 to 2.8 m/s
as borderline, and > 2.8 m/s is highly indicative for manifest PH [1], as in Table-1.
Invasive (mPAP) Non-invasive (systolic TR velocity)
Normal <21 mmHg <2.5 m/s
Borderline 21-25 mmHg 2.5-2.8 m/s
Manifest PH "/>25 mmHg "/>2.8 m/s
mPAP: mean pulmonary artery pressure; TR: Tricuspid regurgitation; m/s: meter/second
Table 1. Definition of pulmonary hypertension [1]
The earliest PH Classification was introduced during a meeting sponsored by World Health
Organization in 1973, basically this classification separated PH into two broad categories:
primary or idiopathic (no identifiable causes can be found) and secondary (cause can be
identified). Then in 1983 the Evian classification was proposed based on pathophysiological
mechanism, clinical presentation and therapeutic options. PH Classification underwent two
major modifications in Venice, Italy in 2003: the term idiopathic pulmonary arterial hyperten‐
sion (IPAH) replaced the term primary pulmonary hypertension and, combined pulmonary
veno-occlusive disease (PVOD) and pulmonary capillary hemangiomatosis (PCH) from
separate categories into a single subcategory of pulmonary arterial hypertension (PAH) [5] [6].
The latest classification (Dana Point classification) became available in 2008 during the 4th
World Symposium on Pulmonary Hypertension, in which PH is categorized into five groups:
Group I: Pulmonary arterial hypertension (PAH); Group II: PH owing to left heart diseases;
Group III: PH owing to lung diseases and/or hypoxeia; Group IV: Chronic thromboembolic
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pulmonary hypertension; Group V: Others (Tumor obstruction, fibrosing mediastinitis,
chronic renal failure on dialysis). [5] [6], and is presented in Table-2.
Subcategory of pulmonary hypertension Hemodynamics
I Pulmonary arterial hypertension (PAH): idiopathic or inheritable PAH
A. Idiopathic
B. Infectious
C. Connective tissue disorders
D. Congenital heart diseases
Pre-capillary
mPAP ≥25 mmHg
PCWP ≤15 mmHg
CO normal or reduced+
II Pulmonary (venous) hypertension because of left-heart disease (PH
with left-heart diseases)
Post-capillary,
mPAP ≥25 mmHg
PCWP "/>15 mmHg
CO normal or reduced+
III Pulmonary hypertension associated with lung diseases and/or
hypoxemia (PH with lung diseases)
Pre-capillary
mPAP ≥25 mmHg
PCWP≤15 mmHg
CO normal or reduced+
Passive: TPG≤12 mmHg
Reactive: TPG"/>12 mmHg
IV Pulmonary hypertension associated with chronic thrombotic and/or
embolic disease (PH with thromboembolic diseases)
Pre- capillary
mPAP ≥25 mmHg
PCWP ≤15 mmHg
CO normal or reduced+
V Pulmonary hypertension associated with unclear and/or
multifactorial mechanisms. Functional versus pathophysiologic
considerations are important issue in classification. A more detailed
description of PH Classification is available in other chapters of the
book
Pre-capillary
mPAP ≥25 mmHg
PCWP ≤15 mmHg
CO normal or reduced+
PAH: Pulmonary arterial hypertension; PH: Pulmonary hypertension; mPAP: mean pulmonary artery pressure; PCWP:
pulmonary artery wedge pressure; TPG: transpulmonary pressure gradient (P¯pa - P¯pcw). #: all values measured at rest;
+: high CO can be present in cases of hyperkinetic conditions such as systemic-to-pulmonary shunts (only in the pulmonary
circulation), anemia, hyperthyroidism, etc.
Table 2. DANA POINT Classification of Pulmonary Hypertension [5] [6]
3. Epidemiology of pulmonary hypertension
A review of a large U.S. database by Memtsoudis et al was undertaken to identify mortality in
patients undergoing total hip arthroplasty (THA) and total knee arthroplasty (TKA).[7] The
authors studied 1359 THA and 2184 TKA patients who also carried the diagnosis of PH. In
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comparison to a demographically-matched group of patients without PH, the THA patients
demonstrated a 4-fold increased adjusted risk of in-hospital mortality and the TKA patients
demonstrated a 4.5-fold increase (p<.001) [7]. Lai et al analyzed 62 patients with PH who
underwent non-cardiac, non-local anesthetic surgery; they found that PH is an important
predictor of adverse cardiopulmonary outcome in non-cardiac surgery as reflected by
markedly increased postoperative complications, especially in patients with coexistent high-
risk clinical and surgical characteristics [8]. Their results are listed in Table-3.
Control (N=62) PH (N=62) P value
Morbidity %
Heart failure %
Delayed extubation"/>24 hours %
Stroke %
Myocardial ischemia/infarct %
Major dysrhythmia %
2 (3.2)
0(0)
2(3.2)
0(0)
0(0)
0(0)
15 (24.2)
6 (9.7)
13(21)
1(1.6)
1(1.6)
2(3.2)
0.002
0.028
0.004
NS
NS
NS
Mortality(in hospital death %) 0(0) 6(9.7) 0.028
PH= Pulmonary Hypertension
Table 3. Postoperative morbidity in patients with Pulmonary Hypertension [8]
Strange et al estimated community-based prevalence of PH in a district in Australia. They studied
10,314 individuals (6.2% of the surrounding Armadale community population) between 2003
and 2009 and they had 15,633 echocardiographic studies performed, 3,320 patients (32%) had
insufficient tricuspid regurgitant (TR) or echocardiographic pulmonary artery systolic pres‐
sure (ePASP, echocardiographical calculation of PASP requires the measurement of regurgi‐
tant flow’s Doppler velocity) and 936 individuals (9.1%) identified having PH regardless of
etiology (defined as ePASP > 40 mmHg). Their minimum 'indicative' prevalence for all forms of
PH is 326 cases/100,000 inhabitants of the local population, with left heart disease-associated PH
being the most common cause (250 cases/100,000); these patients with PH secondary to left heart
disease also had the worst prognosis. They identified 15 cases of pulmonary arterial hyperten‐
sion/100,000 inhabitants and an additional 144 individuals (15% of all patients with PH) with no
identifiable cause for their PH. The mean time to death for those with ePASP >40 mmHg
(calculated from the first recorded ePASP) was 4.1 years. PH increased mortality regardless of
the underlying causes, with those with idiopathic pulmonary arterial hypertension (IPAH)
receiving disease-specific treatment having the best prognoses. Risk of death increased with PH
severity: severe PH shortened the lifespan by an average of 1.1 years compared with mild PH
[9]. Recent hemodynamic studies performed in large cohorts of adult patients with sickle cell
disease have estimated the prevalence of PH in this disease group to be about 6 to 10% [10]. Over
half of these patients have postcapillary PH. Precapilliary arterial PH seems to be a relatively
infrequent complication of sickle cell disease. It is characterized by a different hemodynamic
profile from IPAH with lower levels of PAP and PVR. However, pulmonary vascular disease
appears to have a significant impact on the functional status and vital prognosis of patients with
Pulmonary Hypertension198
sickle cell disease. The predictive value of echocardiography to detect PH in this patient
population is low (25-32%) when the threshold of tricuspid regurgitation velocity of 2.5m/s is
used. At present, no specific treatment is currently approved for the treatment of PH associat‐
ed with sickle cell disease due to lack of data in this specific population [10].
PH frequently accompanies childhood congenital heart disease (CHD) and may persist into
adult life. The advent of specific therapies for PH prompted formation of a national Australia
and New Zealand registry in 2010 to record the incidence, demographics, presentation and
outcomes for these patients. They established a multicenter, prospective, web-based registry
which enrolls patients with CHD-associated PH who are being followed at a tertiary medical
center. The inclusion criteria stipulate patient age >16 years, a measured mPAP >25mmHg at
rest or echocardiographic evidence of PH or a diagnosis of Eisenmenger’s syndrome, and these
patients have been followed since 1/1/2000. The investigators obtained the following results:
of the first 50 patients enrolled, 30 (60%) are female, the mean age [Standard Deviation (SD)]
at the time of PH diagnosis or confirmation in an adult center was 27.23 years (SD=10.07) and
32 patients (64%) are currently aged >30 years. Fourteen (28%) patients were in WHO func‐
tional Class (Table-4) II and 36 (72%) in Class III at the time of diagnosis. Forty-seven of 50
(94%) had congenital systemic-pulmonary shunts and 36 (72%) never underwent intervention.
13 (26%) had Down's syndrome. Confirmation of PH by recent cardiac catheterization was
available in 30 (60%) subjects. During follow-up a total of 32 (64%) patients received a PH
specific therapy. They concluded that CHD-associated PH in adult life has resulted in a new
population with unique needs. This registry will allow documentation of clinical courses and
long-term outcomes for these patients [11].
Class Functional status of patients with pulmonary hypertension
I Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical
activity does not cause undue dyspnea or fatigue, chest pain or near syncope.
II Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are
comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near
syncope.
III Patients with pulmonary hypertension resulting in marked limitation of physical activity. These patients are
comfortable at rest, but less than ordinary physical activity causes undue dyspnea or fatigue, chest pain or
near syncope.
IV Patients with pulmonary hypertension resulting in inability to perform any physical activity without
symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present at
rest, and discomfort is increased by any physical activity.
*--Modified from the New York Heart Association classification of patients with cardiac disease. Adapted with permission
from Rich S., ed. Executive summary from the World symposium on Primary Pulmonary Hypertension 1998, Evian, France,
September 6-10, 1998, cosponsored by the World health Organization. Retrieved April 14, 2000, from the World Wide
Web: http://www.who.int/ncd/cvd/pph.html.
Table 4. WHO Functional Assessment of Patients with Pulmonary Hypertension*
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PH can complicate interstitial lung disease (ILD). Anderson et al evaluated 212 ILD patients
and found that PH occurred in 14% of a cohort of patients with ILD and was associated with
lower lung function parameters. Mortality was markedly higher in ILD patients with PH, and
the presence of PH reduced 6 Minutes Walk Test (MWT) independently of lung function. The
present results emphasize the need for intensified treatment of patients with ILD and PH [12].
4. Etiologies of pulmonary hypertension
1. Causes of pulmonary arterial hypertension(PAH) [1]:
a. Idiopathic PAH (IPAH): No identifiable cause for the PH;
b. Familial PAH: A family history can be reported.
c. PAH associated with other diseases (APAH): Patient’s PH can be associated with other
co-existing diseases such as connective tissue diseases, infectious diseases as HIV
infection,
d. Portal hypertension: like in many end-stage liver disease patient, they often have in‐
creased pressure in pulmonary artery;
e. Drugs & toxins: many decongestants containing ephedrine, pseudoephedrine, propyl‐
hexedrine, or oxymetazoline may lead to PAH. Other agents as NSAIDS, sodium and
caffeine can also cause PAH [13]
f. Pulmonary veno-occlusive or capillary hemangiomatosis.
g. Regarding the pathogenesis of PAH, there is a conceptual transition in recent decades
from the traditional view of mechanical obstruction of blood flow leading to elevated
pressure in the pulmonary circulation to cellular growth and vascular remodeling causing
increased pulmonary vasculature resistance [3][4].
2. PH with left-heart diseases: Congenital systemic-to-pulmonary shuts or left-sided atrial
or ventricular diseases. Any congenital abnormality which leads blood circulating from
high-pressure side to the low-pressure pulmonary circulation will have PAH;
3. PH with lung diseases and/or hypoxemia can be caused by following diseases:
a. Chronic obstructive pulmonary diseases
b. Interstitial pulmonary diseases
c. Sleep apnea or other sleep disorders with breathing problems;
d. Alveolar hypoventilation or other causes related hypoxemia
e. Developmental abnormalities.
4. PH caused by thrombotic and/or embolic diseases.
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5. Miscellaneous: sarcoidosis, histocytosis X, lymphangiomatosis, pulmonary vascular
compression by various pathologies.
5. Pathophysiology of pulmonary hypertension
Though a small percentage of patients have idiopathic PH [14], most perioperative patients
with PH acquired PH secondary to either cardiac or pulmonary disease processes or both. Left
sided ventricular or atrial disease and left sided valvular heart disease are common causes of
PH. Both of these conditions increase left atrial pressure and elevate pulmonary venous
pressure (PVP) and lead subsequently to increased PAP. Multiple respiratory diseases can lead
to the development of PH via hypoxia-induced pulmonary vasoconstriction (HPV) or elevated
PVR due to pulmonary fibrosis [15]. Regardless of the cause, all pathways may lead to an
altered vascular endothelium and smooth muscle function through cellular remodeling and
growth [16] [17]. This results in increased vascular contractility or lack of vascular relaxation
in response to various endogenous vasodilator substances. Morphological abnormalities of
the vascular wall are present in all three layers of the pulmonary arteries of patients with PH,
and medial hypertrophy due to overproliferation of smooth muscle cells is a constant feature
of all forms of PH. The classical mechanical concepts of pressure, flow, shear stress, RV wall
stress and impedance have been gradually complemented with the new concepts of cell injury,
repair/remodeling and interactions of complex multi-cellular systems [17]. Integrating these
recent concepts will become critically important in completely understanding the mechanisms
of PH, as we develop new interventions in order to change the prognosis of the patients with
this devastating condition. Since PH can develop in association with many different diseases
and with multiple risk factors, it is believed that the multi-factorial interplay may very likely
be responsible for the pathogenesis of PH. The right ventricle (RV) is a crescent shaped, thin
walled and compliant muscle chamber intended for volume work, not pressure work. Chronic
PH leads to right ventricular hypertrophy (RVH) as a compensatory mechanism. However,
the ability of the RV to adapt is finite and may eventually lead to RV failure. Unlike the
muscular left ventricular chamber, a hypertrophied RV may not tolerate the acute rises in PVR
that are associated with pain, surgical stimulation and positive pressure ventilation. RV failure
and dilatation can lead to left ventricular compression and diminished cardiac output. This in
turn leads to decreased coronary blood flow and perfusion pressure and can become a viscous
cycle that can be difficult for the patient to overcome. The mechanisms for the pathogenesis of
PH can be simply outlined as one or more of the following aspects: vascular remodeling with
narrowness of vascular lumen and increased resistance, abnormal vascular reactivity leading
to persistent vasoconstriction and loss of relaxation, left-side cardiac diseases impeding
pulmonary venous return and various lung diseases compromising the pulmonary vascular
bed leading to increased PVR. Here we discuss the pathophysiological changes of PH:
5.1. Pulmonary vascular inflammation and immune responses
The presence of antinuclear and antiphospholipid antibodies in the serum of patients with PH
has been documented for many years [18]. There is more evidence that lymphoid neogenesis
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occurs in IPAH. Macrophages, mast cells, T- and B- lymphocytes, plasma cells and anti-
endothelial cell antibodies are all present in and around the complex pulmonary vascular
lesions in IPAH patients. Serum levels of IL-1 and IL-6 are high in IPAH patients, and serum
IL-6 levels negatively predict patient survival. However, whether inflammation and aberrant
immune responses in IPAH are cause or consequence remains unknown. Likely PH occurs
when an inflammatory pulmonary arteriolar injury is not resolved by (normally) protective,
innate anti-inflammatory mechanisms. Regulatory T-cells (Tregs) control not only other T-cells
but also regulate monocytes, macrophages, dendritic cells, natural killer cells and B-cells, and
recent evidence suggests that decreased Treg cell number or function may favor the develop‐
ment of PH. For example, conditions associated with PH, such as HIV, systemic sclerosis,
systemic lupus erythematosus (SLE), Hashimoto’s thyroiditis, Sjogren’s Syndrome and the
antiphospholipid syndrome are characterized by abnormal CD4+ T-cell number and function.
Athymic rats lacking T-cells, develop pronounced PH after vascular injury with a vascular
endothelial growth factor receptor blocker. The lungs in these animals are populated by
infiltrating macrophages, mast cells and B cells, similar to human PH lesions. Most impor‐
tantly, PH is prevented by immune reconstitution of Tregs prior to the induction of vascular
injury. Putting these together all points to a possibility that aberrant Treg-cell function in the
face of vascular injury can result in heightened innate and adaptive immune responses that
could initiate and/or worsen the development of PH [19]. There is increasing evidence
suggesting a role for immune deregulation in PH.
PH can potentially respond to immunosuppresive therapy ( glucocorticoids or targeted B cell
depletion) [20]. Sanchez et al reported on treatment of patients with mixed connective tissue
disease or SLE– associated PH, where corticosteroid and cyclophosphamide has been used as
first-line drugs, they found that PAH associated with SLE or mixed connective tissue disease
may respond to a treatment combining glucocorticosteroids and cyclophosphamide and
improve pulmonary hemodynamics. [21]. The effectiveness of B cell depletion is currently
being examined in an NIH-trial studying the effectiveness of rituximab–a chimeric monoclonal
antibody against the protein CD20, primarily expressed by B-cells – for systemic sclerosis-
associated PAH. It is becoming clear that circulating factors can potentially amplify pulmonary
vascular injury, attract immune cells and/or repair cells which respond to a variety of chemo‐
tactic stimulations, suggesting a systemic disease component contributing to the development
or progression of PAH. In the “modern era” of PAH treatments, where standard vasodilation
therapies have failed to reverse or stop the progression of PAH, novel targets such as discrete
immune pathways hold promising alternatives [20][21]. Nevertheless, new drugs and clinical
trials will all require assessing which patients may respond to anti-inflammatory or immune-
modulating treatment strategies.
Several clinical studies indicated that obesity is a risk factor for the development of PH [22]. [23];
however, the mechanisms leading to this association are unknown. It is a well known fact that
adipocytes secrete multiple bioactive mediators that can influence inflammation and tissue
remodeling, suggesting that adipose tissue may per se directly influence the pathogenesis of
PH. One of these mediators by adipocytes is adiponectin which is a protein with a wide range
of metabolic, anti-inflammatory, and anti-proliferative activities. Adiponectin is present in high
concentration in the serum of lean healthy individuals, but decreased level in obesity. There are
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studies suggesting that relative adiponectin-deficiency may contribute to the development of
inflammatory diseases in obesity, and recent animal studies implicate adiponectin in the
pathogenesis of pulmonary hypertension. Experimental studies showed that adiponectin can
reduce lung vascular remodeling in response to inflammation and hypoxia. Moreover, mice
lacking adiponectin can develop a spontaneous lung vascular phenotype characterized by age-
dependent increases in perivascular inflammatory cells and elevated PAP. Some emerging
evidence indicates adiponectin's effects are mediated through anti-inflammatory and anti-
proliferative actions on cells in the lung [22]. PH has been associated with autoimmune disorders
[18] [24].  Cell-free hemoglobin (Hb) exposure alone can be a pathogenic mediator in the
development of PH and when combined with chronic hypoxia, the potential for exacerbation of
PH and vascular remodeling can be significantly more profound. Buehler et al found this Hb-
exposure related PH is also largely mediated by inflammatory process [25].
5.2. Pulmonary vascular endothelial injury, cellular growth and remodeling
Endothelial injury is central to the development of PH, a proliferative vasculopathy of the
pulmonary circulation. Pulmonary vascular remodeling plays an important role in the
sustained development of PH. Platelet-derived growth factor (PDGF) signaling has been
demonstrated to be a major mediator of vascular remodeling implicated in PH. Xing et al
investigated cigarette smoking (CS)-induced PH in rats and the expression of PDGF and PDGF
receptor (PDGFR) in pulmonary artery, they established the association of PDGF signaling
with CS-induced PH. Forty male rats were randomly divided into control group and three
experimental groups that were exposed to CS for 1, 2, and 3 months, respectively. CS signifi‐
cantly increased right ventricular systolic pressure (RVSP) and right ventricular hypertrophy
index (RVHI). Histology staining demonstrated that CS significantly increased the thickness
of pulmonary artery wall and collagen deposition. The expression of PDGFR isoform B
(PDGFR-B) and PDGFR-β were significantly increased at both protein and mRNA levels in
pulmonary artery of rats with CS exposure. Furthermore, Cigarette smoke extract significantly
increased rat pulmonary artery smooth muscle cell (PASMC) proliferation, which was
inhibited by PDGFR inhibitor Imatinib. Thus, their results indicated PDGF signaling is also
implicated in CS-induced PH [26].
PH is a condition for which no disease-modifying therapies exist for the time being. PH is
recognized as proliferative disease of the pulmonary artery (PA). In the experimental new-
born calf model of hypoxia-induced PH, adventitial fibroblasts in the PA wall exhibit height‐
ened replication index. Because elevated PDGFR-β signaling is associated with PH,
Panzhinskiy et al tested the hypothesis that activation of PDGFR-β contributes to fibroblast
proliferation and adventitial remodeling in PH. In their study, newborn calves were exposed
to either ambient air (P(B) = 640 mm Hg) (Neo-C) or high altitude (P(B) = 445 mm Hg) (Neo-
PH) for 2 weeks. PDGFR-β phosphorylation was markedly elevated in PA adventitia of Neo-
PH calves as well as in cultured PA fibroblasts isolated from Neo-PH animals. PDGFR-β
activation with PDGF-BB stimulated higher replication in Neo-PH cells compared to that of
control fibroblasts. PDGF-BB-induced proliferation was dependent on reactive oxygen species
(ROS) generation and extracellular signal regulated kinase1/2 (ERK1/2) activation in both cell
populations, however only Neo-PH cell division via PDGFR-β activation displayed a unique
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dependence on c-Jun N-terminal kinase1 (JNK1) stimulation as the blockade of JNK1 with
SP600125, a pharmacological antagonist of JNK pathway, and JNK1-targeted siRNA blunted
selectively Neo-PH cell proliferation. These data strongly suggest that hypoxia-induced
modified cells engage PDGFR-β-JNK1 axis to confer distinctively heightened proliferation and
adventitial remodeling in PH [27].
It is also known that 15-lipoxygenase (15-LO) plays an important role in chronic PH. Accu‐
mulating evidence for its down-stream participants in the vasoconstriction and remodeling
processes of pulmonary arteries. Zhang et al investigated how hypoxia regulates 15-LO/15-
hydroxyeicosatetraenoic acid (15-HETE) to mediate hypoxic PH, whether hypoxia advances
the pulmonary vascular remodeling through the PDGF/15-LO/15-HETE pathway. What they
found is pulmonary arterial medial thickening caused by hypoxia could be alleviated by
treatment of the hypoxic rats with Imatinib, which was associated with down-regulations of
15-LO-2 expression and 15-HETE production. Moreover, the increases in cell proliferation and
endogenous 15-HETE content by hypoxia were attenuated by the inhibitors of PDGFR-β in
pulmonary artery smooth muscle cells (PASMCs). The effects of PDGF-BB on cell proliferation
and survival were weakened after the administration of 15-LO inhibitors or 15-LO RNA
interference. These results suggest that hypoxia promotes PASMCs proliferation and survival,
contributing to pulmonary vascular medial hypertrophy, which is likely to be mediated via
the PDGF-BB/15-LO-2/15-HETE pathway [28].
5.3. Pulmonary parenchymal diseases/fibrosis
The pathophysiology of PH in parenchymal lung diseases is partially related to hypoxic
pulmonary vasoconstriction (HPV). This category is also called group III PH, namely PH
attributable to lung diseases and/or hypoxia. Group III PH includes chronic obstructive
pulmonary disease (COPD) and interstitial lung diseases (ILD); the most common parenchy‐
mal lung diseases associated with PH. Group III PH also includes sleep-disordered breathing
and hypoventilation from any cause. Other parenchymal lung diseases associated with PH
include sarcoidosis and systemic vasculitis (group V). There are controversies in terms of
managing this group of patients [29].
5.4. Genetics and pharmacogenomics
Genetic factors may predispose some patients to the development or progression of severe PH.
Mutations of the Bone Morphogenetic Type II Receptor (BMPR2) gene and a member of the
transforming growth factor (TGF-β) superfamily were the first described in patients with
familial/hereditary PH [30],[31][32]. Although BMPR2 mutations in PH have a high prevalence
(70%), limited numbers of patients with PH have mutations, and only 20% of the carriers ever
develop PH during their lifetime. BMPR2 mutation carriers at the time of PH diagnosis are
younger and less likely to have a vasoreactive component [33][34]. A large number of muta‐
tions have been reported and the majority cause a loss of function or reduced BMPR2 expres‐
sion. It has been reported that the disease appears to be more severe when patients carry a
truncating BMPR2 mutation. However, this appears not to be the case in the French patients.
Mechanistic studies indicate that BMPR2 mutations are permissive but not necessary for the
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development of severe PH. BMPR2 may be one of the guardians of lung vessel homeostasis,
as gene knockout and silencing experiments have clearly demonstrated that both apoptosis
and cell proliferation of PASMCs and endothelial cells are controlled by BMPR2. Intact BMPR2
signaling may be necessary for the execution of a normal lung vascular wound-healing
program, preventing apoptosis-induced compensatory cell proliferation. BMPR2 loss makes
cells more susceptible to apoptosis, however, vascular cell-apoptosis alone, is insufficient for
angioproliferation to occur. BMPR2 signaling appears to define the cellular identity during
reparative responses. BMP signaling is regulated at many different levels and each level could
potentially contribute to abnormal BMPR-2 function, without necessarily involving a mutation
in the BMPR2 gene. For example, mutations in the type I TGF-receptor, ALK-1, have been
observed in patients with severe PAH occurring in families with hereditary hemorrhagic
telangiectasia. Moreover, although infrequent, mutations in the BMPR-2-downstream medi‐
ators, the smad proteins, have also been described in PH patients. Their data also indicated
that BMP/TGF-β signaling plays an important role in the maintenance of the normal lung
arteriolar structure [30][31]. Epigenetic mechanisms influence gene expression via modifica‐
tions of the chromatin, histones and regulatory micro RNAs. At present, there is no firm
evidence that PH has an epigenetic component. Downregulation of BMPR2 expression has
been explained by activation of a 5 STAT3/miRNA-17-92 microRNA axis in normal human
lung endothelial cells after interleukin-6 exposure. Interestingly, mice overexpressing IL-6
develop severe pulmonary hypertension and, unlike other PH mice models, also develop
angioobliterative vascular remodelling and robust RV hypertrophy. Overexpression of miR-17
also increases proliferation of human PASMCs and inhibition with a specific miR-17 antagonist
ameliorated PH in two experimental models [35] [36]. Another microRNA, miR204, has been
found downregulated in pulmonary artery smooth muscle cells isolated from patients with
PH. Upregulation of miR204 seems to induce an apoptosis-resistant phenotype in smooth
muscle cells [37].
PAH is an uncommon disease in the general population, but a disease with significant
morbidity and mortality. The prevalence of heritable PH remains unknown. The reason for
incomplete penetrance of heritable PAH is not well understood. A patient's clinical response
to disease-specific therapy is complicated with potential involvement of the disease severity,
comorbidities, appropriateness of the prescribed therapy, and patient compliance. Dempsie
et al studied the effects of gender on development of PH in mice with over-expressing Mts1
(Mts1+ mice) by measuring pulmonary arterial remodeling, systolic right ventricular pressure
(sRVP) and RVH. Gender differences in pulmonary arterial Mts1 and the receptor for advanced
glycosylation end products (RAGE) expression were assessed by qRT-PCR and immunohis‐
tochemistry. Western blotting and cell counts were applied to investigate interactions between
17β-estradiol, Mts1 and RAGE on proliferation of human PASMCs. Statistical analysis
methods used were one-way analysis of variance with Dunnetts post test or two-way analysis
of variance with Bonferronis post test, as appropriate. Their results showed that female Mts1+
mice developed increased sRVP and pulmonary vascular remodeling, whereas male Mts1+
mice remained unaffected, and the development of plexiform-like lesions in Mts1+ mice was
specific to females. These changes stained positive for both Mts1 and RAGE in the endothelial
and adventitial layers. Expression of pulmonary arterial Mts1 was greater in female than male
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Mts1+ mice, and was localized to the medial and adventitial layers in non plexiform-like
pulmonary arteries. RAGE gene expression and immunoreactivity were similar between male
and female Mts1+ mice and RAGE staining was localized to the endothelial layer in non
plexiform-like pulmonary arteries adjacent to airways. In non-plexiform like pulmonary
arteries not associated with airways RAGE staining was present in the medial and adventitial
layers. Physiological concentrations of 17β-estradiol increased Mts1 expression in PASMCs,
while 17β-estradiol-induced hPASMC proliferation was inhibited by soluble RAGE, which
antagonizes the membrane bound form of RAGE. Authors believe Mts1 over-expression
combined with female gender is permissive to the development of experimental PAH in mice.
Up-regulation of Mts1 and subsequent activation of RAGE may contribute to 17β-estradiol-
induced proliferation of hPASMCs [38].
5.5. Chronic pulmonary thromboembolic events
Chronic thromboembolic events may lead to PH. Long-standing thromboembolic obstruction
of pulmonary arterial vasculature by acute or recurrent thromboemboli with subsequent
organization can cause progressive PH and RVF. Advances in diagnostic modalities and
surgical pulmonary endarterectomy techniques have made this PH induced by these chronic
thromboembolization treatable and even potentially preventable and/or curable. Although
published guidelines are available, in the absence of randomized controlled trials regarding
chronic thromboembolic PH, there is a lack of standardization, and treatment options have to
be individualized [39].
5.6. Exercise-induced pulmonary hypertension
Though exercise-induced increase in pulmonary arterial pressure has been removed fromn
current PH Classification, exercise stress tests of the pulmonary circulation can potentially help
detect early or latent pulmonary vascular disease and may help understand the clinical
evolution and effects of treatments in patients with established PH. Exercise stresses the
pulmonary circulation through increases in cardiac output and left atrial pressure. Recent
studies have shown that exercise-induced increase in PAP is associated with dyspnea-fatigue
symptomatology, validating the notion of exercise-induced PH. Exercise in established PH has
no diagnostic relevance, but may help in the understanding of changes in functional state and
the effects of therapies [40] [41].
5.7. Chronic hypoxemia
Chronic hypoxic lung diseases can lead to PH which subsequently increases patients’ mor‐
bidity and mortality. Since the identification of heterozygous morphogenetic protein (BMP)
receptor mutations as the underlying factor in the rare heritable form of pulmonary arterial
hypertension, the important role of altered BMP signaling in PH was then significantly more
appreciated [42] [43]. Later studies demonstrated that BMP signaling was also reduced in other
more common forms of PH. The mechanism of the BMP signaling reduction was recently
elucidated by Cahill and associates. They found that expression of 2 BMP antagonists, Gremlin
1 and Gremlin 2 was significantly higher in the lung than in other organ systems. And Gremlin
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1 was further increased in the walls of small intrapulmonary vessels of mice during the
development of hypoxic PH. In vitro studies showed that hypoxia stimulated cultured human
pulmonary microvascular endothelial cells to secrete Gremlin secretion which inhibited
endothelial BMP signaling and BMP-stimulated endothelial repair. Haplodeficiency of
Gremlin 1 augmented BMP signaling in the hypoxic mouse lung and reduced PVR by
attenuating vascular remodeling. Furthermore, Gremlin was increased in the walls of small
intrapulmonary vessels in IPAH and the rare heritable form of PAH in a distribution suggest‐
ing endothelial localization. Their findings demonstrated the central role for increased Gremlin
in hypoxia-induced pulmonary vascular remodeling and the increased PVR in hypoxic PH.
High levels of basal Gremlin expression in the lung may account for the unique vulnerability
of the pulmonary circulation to heterozygous mutations of BMP type 2 receptor in PAH [42].
Interestingly, digoxin was found to inhibit the development of hypoxemia-induced PH in an
animal model [43]. One of the mechanisms involved in the development of hypoxic PH is
hypoxia-inducible factor 1 (HIF-1)-dependent transactivation of genes controlling pulmonary
arterial smooth muscle cells (PASMC) intracellular calcium concentration ([Ca(2+)](i)) and pH.
Digoxin was shown to inhibit HIF-1 transcriptional activity, and potentially prevent and
reverse the development of PH. And digoxin can attenuate the hypoxia-induced increases in
RV pressure and PASMC pH and [Ca(2+)](i) [42].
The etiologies and mechanisms of PH are illustrated in Figure-1.
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Figure 1. Etiologies and mechanisms of pulmonary hypertension (Illustrated by Henry Liu, MD)
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Figure 2. Top: Apical four-chamber view (systole) showing enlarged right-side chambers with compressed and geo‐
metric distortion of an intrinsically normal LV secondary to marked RV pressure overload; severe TR. RA-right atrium;
LA- left atrium. Bottom: Peak TR velocity of 4.68 m/s, with a peak gradient of 87.8 mm Hg indicating severe PH.
6. Perioperative management of pulmonary hypertension
6.1. Preoperative assessment
Patients with PH undergo surgical procedures with significantly higher risks for morbidity
and mortality regardless of the etiologies of the PH, the types of surgery and the anesthetic
technique [44] [45] [46] [47] [48] [49]. The clinical outcome is especially worse for those with
Eisenmenger’s syndrome. Kahn reported that patients with Eisenmenger’s syndrome under‐
going cesarean section had mortality as high as 70% [50]. Although there is not an overabun‐
dance of literature regarding the development of postoperative pulmonary complications
following noncardiac surgery, the few available studies demonstrate the increased risk
associated with these surgical procedures. Preoperative medical optimization is therefore
necessary. During preoperative risk assessment, one should take into account the type of
surgery, the patient’s functional status, the severity of the PH, the function of the right ventricle
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and any other co-morbidities. Generally superficial procedures and non-orthopedic proce‐
dures are associated with less hemodynamic and sympathetic nervous system perturbations
than more invasive/traumatizing procedures. Orthopedic procedures with bony involvement
can be quite stimulating for the patients and will increase the risk of elevating PVR and RV
failure. Thoracic surgery is associated with significant changes in intrathoracic pressures, lung
volumes and oxygenation, which may cause acute increases in PVR and decreased RV function
[51]. Laparoscopic surgery requires pneumoperitoneum which may be poorly tolerated
because it can decrease preload and increase afterload. Surgical procedures associated with
rapid or massive blood loss will be poorly tolerated by patients with severe PH. WHO
standardized the functional status definition as shown in Table-4.
History and Physical Exam: Preoperative evaluation should include a thorough history and
physical examination with special attention to signs and symptoms of respiratory insufficiency
and right ventricular dysfunction. Symptoms are typically nonspecific with the most frequent
being progressive dyspnea. The signs depend on disease severity and include dyspnea at rest,
low cardiac output with metabolic acidosis, hypoxemia, evidence of right heart failure (large
V wave on jugular vein, peripheral edema, hepatomegaly), and syncope [52]. Laboratory
studies and special tests should be determined by the surgical procedure that the patient is
undergoing and the medication profile of the patient. Routine preoperative tests include
electrocardiography (EKG), chest radiographs (CXR), complete blood counts (CBC), electro‐
lytes, baseline arterial blood gas analysis (ABG), room air oxygen saturation. Although ECG
changes alone cannot determine disease severity or prognosis of PH [53] [54], the ECG may
show signs of right ventricular hypertrophy, such as tall right precordial R waves, right axis
deviation and right ventricular strain [55]. The chest radiography may show evidence of right
ventricular hypertrophy (decreased retrosternal space, cardiomegaly, enlarged cardiac
silhouette) or prominent pulmonary vasculature. CBC will help decide the necessity of
preoperatively optimizing the hematocrit of the patients or not. Plasma electrolytes assess
baseline electrolytes and acid-base disturbances.
Delayed post-exercise heart rate recovery (HRR) has been associated with disability and poor
prognosis in chronic cardiopulmonary diseases. Ramos et al investigated the usefulness of HRR
to predict exercise impairment and mortality in patients with PH. They studied 72 PH patients
with varied etiologies [New York Heart Association (NYHA) classes’ I-IV] and 21 age- and
gender-matched controls. Both groups underwent a maximal incremental cardiopulmonary
exercise test (CPET) with heart rate being recorded up to the fifth minute of recovery. Their
results revealed that HRR was consistently lower in the patients compared with the controls (P
<0.05). The best cutoff for HRR in 1 minute (HRR (1 min)) to discriminate the patients from the
controls was 18 beats. Compared with patients with HRR (1 min) ≤ 18 (n = 40), those with HRR
(1 min) >18 (n = 32) had better NYHA scores, resting hemodynamics and 6-minute walking
distance (6MWD). In fact, HRR (1 min) >18 was associated with a range of maximal and
submaximal CPET variables indicative of less severe exercise impairment (P < 0.05). The single
independent predictor of HRR (1 min) ≤ 18 was the 6MWD (odds ratio 0.99, P < 0.05). On a multiple
regression analysis that considered only CPET-independent variables, HRR (1 min) ≤ 18 was the
single predictor of mortality (hazard ratio 1.19, P < 0.05). Thus they concluded preserved HRR(1
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min) (>18 beats) is associated with less impaired responses to incremental exercise in patients
with PH. To the contrary, a delayed HRR (1 min) response has negative prognostic implica‐
tions, a finding likely to be clinically useful when more complicated (and costlier) analyses
provided by a full CPET are not available [56]. Minai et al had a similar finding: they evaluate
the association between HRR at 1 minute of rest (HRR1) after 6-min walk test (6MW test) and
clinical worsening in patients with IPAH. HRR (1 min) was defined as the difference in heart
rate at the end of 6MW test and at 1 minute after completion of the 6MW test. Seventy-five
consecutive patients with IPAH underwent 6MW test and were included in the analysis. The
results showed those patients with HRR1 less than 16 (n = 30) were more likely to have clinical
worsening (odds ratio, 9.7, P < 0.001) and shorter time to first clinical worsening event (TCW)
(6.7 mo vs. 13 mo; P < 0.001) during follow-up. With multivariable analysis, the best predictors
of clinical worsening were HRR (1 min) less than 16 (hazard ratio, 5.2, P = 0.002) and mean PAP
(hazard ratio, 1.04, P = 0.02). Compared with the distance walked during the 6MW test (6MW
test), HRR (1 min) less than 16 was a better predictor of clinical worsening and TCW. The addition
of HRR (1 min) increased the ability of 6MWD to predict clinical worsening events. HRR (1 min)
after 6MW test is a strong predictor of clinical worsening and TCW in patients with IPAH. The
addition of HRR (1 min) to 6MWD increases the capacity of 6MWD to predict clinical worsen‐
ing and TCW in patients with IPAH [56].
Additional tests which can potentially benefit patients include echocardiography, right heart
catheterization, pulmonary function testing, ventilation/perfusion (V/Q) scanning, pulmonary
angiography, spiral computed tomography, serologic testing, liver function testing, and N-
terminal pro-B-type natriuretic peptide (NT-proBNP). Among these available tests, echocar‐
diography is probably the best screening study. Echocardiography is used to assess right
ventricular (RV) size, function and estimate pulmonary artery pressures [52]. Echocardiogra‐
phy is a useful tool for both assessment and monitoring of disease progression in PH. Although
transthoracic echocardiography is the most widely used modality for this purpose, especially
for the initial PH evaluation, transesophageal echocardiography (TEE) can be a more useful
technology for patients with poor acoustic windows and for intraoperative monitoring.
Compared to other monitoring modalities, TEE can be particularly useful in narrowing the
differential diagnoses for intraoperative hemodynamic instability (hypovolemia, hypervole‐
mia, right or left ventricular ischemia/failure) and in formulating a therapeutic plan. Multiple
echocardiographic methods, M-mode, 2D and real-time 3D have been utilized to assess PH.
The usual echocardiographic findings associated with PH include the following: 1). enlarged
right atrial or right ventricular (RV) chambers; 2) mid-systolic closure or notching of the
pulmonary valve; 3) diminished or absent atrial wave of the pulmonary valve; 4) intraven‐
tricular septal flattening; 5) paradoxical systolic motion of the intraventricular septum (IVS)
toward the left ventricle; 6) a dilated inferior vena cava with reduced respiratory variability;
7) increased IVS/posterior left ventricular (LV) wall ratio (>1); 8) increased RV end-diastolic
volume index; 9) increased RV endsystolic volume index, and 10) decreased RV ejection
fraction [58] [59] [60]. 11). right ventricular enlargement with tricuspid regurgitation, small left
ventricle with an asymmetric hypetrophic wall, with ventricular stiffness and diastolic
incompetence [61]. Methods used to determine PAP by echocardiography include: measure‐
ment of the tricuspid annular plane systolic excursion (TAPSE), two-dimensional strain, tissue
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Doppler echocardiography, the speckle tracking method, acceleration time across the pul‐
monic valve, the pulmonary artery regurgitant jet method and the tricuspid regurgitant jet
method [62]. The tricuspid regurgitant jet method is most commonly used for determination
of the pulmonary artery systolic pressure (PASP). The simplified Bernoulli equation, Pressure
gradient (P1 – P2) = 4V2, where V is the peak velocity, is used to approximate the PASP by
continuous wave Doppler across the tricuspid valve regurgitant jet. In this case, RVSP ≈ PASP
= 4V2 + RAP, where RVSP is the right ventricular systolic pressure and RAP is the right atrial
pressure. The RVSP approximates PASP when no pulmonary valve stenosis or right ventric‐
ular outflow obstruction exists [62]. Although right heart catheterization (RHC) remains the
gold standard for assessment of hemodynamic parameters in PH, advantages of echocardiog‐
raphy include wide availability, noninvasive modality, and lower costs. Intraoperatively, TEE
allows dynamic interpretation and assessment of the therapeutic management of PH. Disad‐
vantages include the need for specialized training for interpretation, modest diagnostic
accuracy and the correlation to PH as compared to RHC [ 62] [63]. Janda et al revealed that the
correlation coefficient of systolic pulmonary artery pressure (PASP) by echocardiography as
compared with PASP by RHC to be 0.70 (95% CI 0.67 to 0.73) as well as a summary sensitivity
and specificity of 83% (95% CI 73 to 90) and 72% (95% CI 53 to 85), respectively for diagnostic
accuracy of echocardiography for pulmonary hypertension [62]. The variability of echocar‐
diography to correlate to RHC is in part related to the underlying disease, lung conditions,
time of the examination, and the skills of the echocardiographer [51] [64] [65]. Underestimation
of PASP by echocardiography resulting in improper classification of PH (mild, moderate,
severe) is more likely than overestimation, however inaccuracy in both under and over-
estimation occur with similar frequency [64]. Improvement in obtaining the tricuspid regur‐
gitant jet peak velocity has been found with the use of an intravenous bolus of agitated saline
[58] [59] [66]. Despite the technical challenges and inaccuracies associated with echocardiog‐
raphy, it remains a useful tool, especially for perioperative management of patients with PH.
For the initial evaluation, monitoring, and management of PH. Takatsuki et al evaluated the
usefulness of tissue Doppler imaging (TDI) in assessment of disease severity and prognostic
value in children with IPAH. The authors studied TDI velocities (systolic myocardial velocity,
early diastolic myocardial relaxation velocity [Em], late diastolic myocardial velocity associ‐
ated with atrial contraction), brain natriuretic peptide, NYHA functional class, and hemody‐
namic parameters in 51 children (mean age; 11.6 years) with IPAH. Fifty-one healthy children
with comparable demographics served as controls. They found that Tricuspid Em had
significant inverse correlations with plasma brain natriuretic peptide levels (r= -0.60, P < 0.001),
right ventricular end-diastolic pressure (r= -0.79, P < 0.001), and mean PAP (r=-0.67, P < 0.001).
Em, Em/late diastolic myocardial velocity associated with atrial contraction ratio, and systolic
myocardial velocity at mitral annulus, septum, and tricuspid annulus in IPAH were signifi‐
cantly reduced compared with controls. Statistically significant differences were observed in
tricuspid Em between NYHA functional class II versus combined III and IV (mean and SD;
11.9 ± 4.2 cm/s versus 8.2 ± 3.6 cm/s, respectively, P= 0.002). Cumulative event-free survival
rate was significantly lower when tricuspid Em was ≤8 cm/s (log-rank test, P< 0.001). So they
believe Tricuspid Em velocity correlated with NYHA functional class as disease severity and
may serve as a useful prognostic marker in children with IPAH. [67].
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6.1.1. Right heart catheterization
Right heart catheterization is considered the gold standard for measuring PAP. Evidence of
significant RV dysfunction should prompt reevaluation of the need for surgery [68]. All
attempts to lower PAP should be done preoperatively. Treatment options include oxygen,
bronchodilators, vasodilators and inotropes. In addition to the careful evaluation of the
patient’s current therapeutic regimen for pulmonary hypertension, all other medications
should be reviewed for possible drug-drug interactions. Likewise, it is important to maintain
the patient’s current therapeutic regimen as discontinuation of medications can potentially
lead to rebound or even worsened PH and RV dysfunction. Although medications such as
inhaled prostacyclin (epoprostenol or Flolan) are associated with impaired platelet aggrega‐
tion, they have not been implicated in clinically significant bleeding. Due to the short half-life
of this medication, epoprostenol should not be stopped at any time in the perioperative period.
The anesthesiologist must ensure preoperative maximization of the patient’s therapeutic
options being accomplished and coordinated, if needed, a perioperative strategy for continu‐
ance of chronic PH therapy [69].
6.1.2. Pulmonary function tests, ventilation/perfusion (V/Q) scanning and pulmonary angiography
Pulmonay function test (PFT) has been used for the assessment of the overall pulmonary function.
PFT can help determine patient’s tolerability to certain surgical procedures. He et al conducted
V/Q scanning and computed tomography pulmonary angiography (CTPA) for a total of 114
consecutive patients (49 men and 65 women, average age 43.3 years) suspected of having CTEPH.
Interpretation of V/Q images was based on the refined Pulmonary Embolism Diagnosis criteria.
For  threshold  1,  high-probability  and  intermediate-probability  V/Q  scan  findings  were
considered to be positive, and low-probability/normal V/Q scan findings were negative. For
threshold 2, only a high-probability V/Q scan finding was considered to be positive. And
intermediate-probability and low-probability/normal V/Q scan findings were considered to be
negative. Their results indicated that 51 patients (44.7%) had a final diagnosis of CTEPH. V/Q
scan showed high probability (52 patients), intermediate probability (2 patients), and low
probability/normal scan (59 patients) respectively. CTPA revealed 50 patients with CTEPH and
64 patients without CTEPH. The sensitivity, specificity, and accuracy of the V/Q scan were 100,
93.7, and 96.5%, respectively, with threshold 1, and 96.1, 95.2, and 95.6%, respectively, with
threshold 2; similarly, the sensitivity, specificity, and accuracy of CTPA were 92.2, 95.2, and
93.9%, respectively. They therefore concluded that both V/Q scanning and CTPA are accurate
methods for the detection of CTEPH with excellent diagnostic efficacy [70].
6.1.3. Cardiac Magnetic Resonance Imaging (MRI)
Cardiac magnetic resonance imaging (MRI) has prognostic value in patients with IPAH before
starting intravenous prostacyclin [71]. Swift et al studied the diagnostic accuracy of MRI
derived RV measurements for the detection of pulmonary hypertension (PH) in the assessment
of patients with suspected PH. They retrospectively reviewed 233 treatment-naïve patients
with suspected PH including 39 patients with no PH who underwent MRI and right heart
catheterization (RHC) within 48 hours. The diagnostic accuracy of multiple MRI measure‐
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ments for the detection of mPAP [greater than or equal to] 25 mmHg was assessed using
Fisher's exact test and receiver operating characteristic (ROC) analysis. Ventricular mass index
(VMI) was the MRI measurement with the strongest correlation with mPAP (r=0.78) and the
highest diagnostic accuracy for the diagnosis of PH (area under the ROC curve of 0.91)
compared to an ROC of 0.88 for mPAP measured by echocardiography. Using late gadolinium
enhancement, VMI [greater than or equal to] 0.4, retrograde flow [greater than or equal to] 0.3
L/min/m2 and PA relative area change [less than or equal to] 15% predicted the presence of
PH with a high degree of diagnostic certainty with a positive predictive value of 98%, 97%,
95% and 94% respectively. No single MRI parameter could definitely exclude the presence of
PH. Thus they concluded that MRI is a useful alternative to echocardiography in the evaluation
of suspected PH. They support the routine measurement of ventricular mass index, late
gadolinium enhancement and the use of phase contrast imaging in addition to right heart
functional indices in patients undergoing diagnostic MRI evaluation for suspected pulmonary
hypertension [72].
6.1.4. N-Terminal pro-B-type Natriuretic Peptide (NT-proBNP)
Frantz et al used N-terminal pro-B-type natriuretic peptide (NT-proBNP) as a biomarker of the
disease severity in patients with PAH. They aimed to determine whether baseline NT-proBNP
levels correlate with improvement in 6MWD in the pivotal randomized, placebo-controlled,
double-blind study of the addition of inhaled treprostinil to oral therapy for PH. They found
that baseline NT-proBNP levels demonstrated a strong correlation with treatment in predicting
change from baseline for 6MWD (p < 0.01), indicating that in the upper quartile (≥1,513.5 pg/
ml), patients on inhaled treprostinil had a better response (+64 versus +32 m), whereas patients
on placebo fared worse (-13 versus +20 m) when compared with the lower 3 quartiles (<1,513.5
pg/ml). Furthermore, least-squares mean difference in 6MWD between active and placebo
groups was +67 and +16 m for the upper and lower 3 quartiles of NT-proBNP, respectively.
The investigators concluded that greater improvement in 6MWD in actively treated patients
with high levels of NT-proBNP predicts better clinical response to inhaled treprostinil in more
advanced disease [73]. Diller et al followed up 181 patients (mean follow-up period is 3.3 years,
7 patients with Down syndrome) with 20 deaths. Their results showed that higher BNP
concentrations were predictive of all cause mortality on univariate analysis in patients with or
without Down syndrome. On multivariable Cox proportional hazard analysis, BNP predicted
survival independently of renal function, Down syndrome, or 6MWD (p=0.004). Temporal
increases in BNP concentration also predicted mortality in patients with concurrent Eisen‐
menger syndrome patients. Treatment with disease targeting therapies was associated with a
significant reduction in BNP concentrations [74].
Perioperative Risks of PH: The patient with PH is at elevated risk for morbidity and mortality
in the perioperative period [5], [76], [77], [78]. There is a relative paucity of literature studying
outcomes in this patient population presenting for noncardiac surgery, however, the evidence
that does exist points to significantly increased potential for complications in the perioperative
period. Ramakrishna et al presented the results from an overview of 145 patients with PH
presenting for noncardiac surgery. A 42% rate of early (<30 days) morbidity (congestive heart
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failure, cardiac ischemic event, stroke, respiratory failure, hepatic or renal disfunction, cardiac
dysrhythmia) and a 9.7% rate of early mortality in this population have been reported [47].
Ramakrishna et al summarized the clinical characteristics associated with early morbidity and
mortality in Table-5.
Clinical characteristics prone to early mortality Clinical characteristics prone to early morbidity
1. Right axis deviation (RAD)
2. Right ventricular hypertrophy (RVH)
3. RVSP/SBP ratio above 0.6
4. Intraoperative use of epinephrine or dopamine
1. NYHA class 2 or higher
2. History of pulmonary embolism
3. Obstructive sleep apnea
4. High-risk surgery
5. Anesthesia duration 3 hours or longer
6. Intraoperative use of epinephrine or dopamine
NYHA=New York Heart Association, RVSP=right ventricular systolic pressure, SBP=systolic blood pressure.
Table 5. Clinical characteristics associated with increased morbility and mortality in PA patients. Modified from
reference [47].
Lai et al. performed a case-control study examining 67 patients with pulmonary systolic
pressures greater than 70 mmHg compared to controls with normal pulmonary pressures [8].
As shown in Table-4, the pulmonary hypertension group developed postoperative heart
failure more frequently (9.7 vs. 0%, p =.028), delayed tracheal extubation (21 vs. 0%, p =.004)
and greater in hospital mortality (9.7 vs. 0%, p = 0.004). A review of a large U.S. database by
Memtsoudis et al. estimated the mortality rate in patients undergoing total hip arthroplasty
(THA) and total knee arthroplasty (TKA) [7]. The authors identified 1359 THA and 2184 TKA
patients with the diagnosis of PH. In comparison to a matched sample without PH, the THA
patients had a 4-fold increased adjusted risk of in-hospital mortality and the TKA patients had
a 4.5-fold increase (p< 0.001) [7]. Patients with PH are at considerably increased risk in the
perioperative period morbidity and mortality. [8].
6.2. Intraoperative considerations
Dependent upon the nature of the scheduled surgical procedure, various anesthesia techniques
including general anesthesia, neuraxial anesthesia, peripheral nerve blockade and monitored
anesthesia care (MAC) have been reported to be success in the management of patients with
PH [45] [79]. Except for few case reports, very little literature exists evaluating the differences
of these management strategies for intraoperative and postoperative management of the
patient with PH. Furthermore the choice of technique is less important as the ability to adhere
to the goals of avoiding elevations in PVR and RHF.
For major procedures in patients with PH, routine ASA standard monitoring should be
utilized. The following additional strategies are potentially critical for the appropriate
perioperative management of patients with PH:
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1. Arterial line for the continuous monitoring of arterial pressure. By using arterial pressure
monitoring we can ensure adequate perfusion pressures for all vital organs including
heart, lungs and brain. Arterial line can also be used for frequent blood gas analysis.
2. Pulmonary artery catheterization (PAC): PAC can be used for the monitoring of pulmo‐
nary artery pressure, for the measurement of CO and for the measurement of mixed
venous oxygen saturation. By measuring PCWP, PAC can help determine left ventricular
preload in pulmonary hypertensive patients whose cardiac output is limited by right
ventricular function. PAP measurement is also critical in determining PH severity, and
choice and dosing of therapeutic agents. However, intraoperative PAC placement is
controversial in patients with PH because of the potential complications due to PAC
placement. Hoeper et al performed a multicenter 5-year retrospective and 6-month
prospective evaluation of serious adverse events related to right heart catheter procedures
in patients with pulmonary hypertension, as defined by a mean pulmonary artery
pressure >25 mm Hg. Out of total 7218 PAC procedures, they found the overall number
of serious adverse events was 76 (1.1%). The most frequent complications were related to
venous access (e.g., hematoma, pneumothorax), followed by arrhythmias and hypoten‐
sive episodes related to vagal reactions or pulmonary vasoreactivity testing. The vast
majority of these complications were mild to moderate in intensity and resolved either
spontaneously or after appropriate intervention. Four fatal events were recorded in
association with any of the catheter procedures, resulting in an overall procedure-related
mortality of 0.055%. Thus they believe that in experienced centers, right heart catheter
procedures in patients with pulmonary hypertension are still safe, only associated with
low morbidity and mortality rates [80].
3. Central venous pressure (CVP) may be a more accurate guide for volume administration.
Care should be taken in placing PAC and/or CVP catheters as these patients are reliant
on sequential atrial-ventricular contraction for adequate preload and cardiac output.
Arrhythmias associated with catheter insertion may not be well tolerated by these
patients.
4. Non-invasive or minimally invasive CO measurement techniques may also be useful in
PH patients undergoing surgical procedures and labor and delivery [81].
5. Bispectral index score (BIS) monitoring helps maintain appropriate depth of anesthesia.
6. Transesophageal echocardiography (TEE): Transesophageal echocardiography can be
very useful in assessing the preload, contractility, anatomical irregularities and valvular
abnormalities of both right-side and left-side of the heart. TEE can also help evaluate the
result of cardiopulmonary surgical procedures [82] [83].
6.3. Strategies of controlling pulmonary arterial pressure
There are multiple methods available to control the increased PAP intraoperatively. These
strategies can be categorized into pharmacological and non-pharmacological measures.
Pharmacological management of intraoperative hypertension includes the following:
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1. Inhaled nitric oxide: Inhaled nitric oxide (INO) is one of the most potent medications
commonly used perioperatively. The usual dose is 20–80 ppm (parts per million). The
delivery system is shown in Figure-3. The INO delivery system includes a circuit and a
control panel and related tank and tubing. INO can diffuse from the alveoli to the
pulmonary capillaries and stimulates guanylate cyclase to increase cyclic guanosine
monophosphate (cGMP) which leads to vasodilation. INO does not produce systemic
vasodilatation because nitric oxide is inactivated when bound to hemoglobin. It also has
the benefit of improving ventilation– perfusion matching by increasing perfusion to areas
of the lung that are well ventilated. If the clinical picture is of pulmonary hypertension
with systemic hypotension, IV vasodilators may cause worsening of systemic blood
pressure, subsequent RV hypoperfusion, ischemia and failure. In this situation, the patient
may benefit from therapy selective for the pulmonary vasculature such as inhaled nitric
oxide (INO) or prostacyclin. INO has also been shown to improve PH in cardiopulmonary
bypass settings [84] [85].
 
 
 
  
Figure 3. Inhaled nitric oxide delivery system Left: Inhaled nitric oxide delivery system control panel. Right: Inhaled
nitric oxide delivery circuit, the arrow indicates the inspiratory limb. (Copyright owned by Henry Liu, MD)
2. Milrinone: Milrinone is a phosphodiesterase-3 inhibitor and prevents the breakdown of
cyclic adenosine monophosphate (cAMP). It has shown to reduce both PVR and SVR in
addition to causing increases in myocardial contractility [86]. The usual dose of milrinone
is 50 mg/kg loading, then 0.5–0.75mg/kg/min for the maintenance.
3. Thromboxane synthase inhibitor:  Dipyridamole (tradename: Persantine) can be used
intraoperatively in managing PH; its usual dose is 0.2–0.6 mg/kg i.v. over 15 minutes,
and it  may be repeated after 12 hours.  Lepore et  al  used intravenous dipyridamole
combined with INO in 9 patients with congestive heart failure (CHF) and severe PH
who were breathing 100% oxygen during right heart catheterization, we administered
inhaled NO (80 ppm) alone and in combination with intravenous dipyridamole (0.2-mg/
kg bolus, with an infusion of 0.0375 mg/kg/min), and found that Intravenous dipyrida‐
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mole augments and prolongs the pulmonary vasodilator effects of INO in CHF patients
with severe PH [87].
4. Inhaled prostacyclin: Continuous intravenous administration of prostacyclin 50 ng/kg/min
after  reconstituting  prostacyclin  in  sterile  glycine  diluent  to  30,000  ng/ml  (1.5mg of
prostacyclin in 50 ml of diluent). For an 80 kg patient, 50 ng/kg/min is 8 ml of this solution
per hour. It is nebulized into the inspiratory side of the ventilator circuit; an example of a
prostacyclin nebulized delivery system that can be integrated into the anesthesia circuit is
shown in Figure-4. Iloprost is a synthetic analogue of prostacyclin PGI2. Iloprost dilates
systemic and pulmonary arterial vascular beds. It also affects platelet aggregation but the
relevance of this effect to the treatment of pulmonary hypertension is unknown. The two
diastereoisomers of iloprost differ in their potency in dilating blood vessels, with the 4S
isomer substantially more potent than the 4R isomer. Prostacyclin, available in inhaled and
intravenous forms,  stimulates  adenylate  cyclase  and increases  cAMP and release  of
endothelial NO leading to decreases in PAP, RAP, and increased cardiac output [88].
Combination therapy, with both INO and prostacyclin, has synergistic effects compared to
monotherapy [89] [90]. Due to the extremely short half-life of these medications, one should
ensure that the medication is delivered continuously without interruption to minimize the
risk of rebound PH. Weaning from these medications should be performed gradually with
frequent assessment of PAP and RV function. A disadvantage of INO compared to inhaled
prostacyclin is its high cost. A recent analysis revealed that INO is approximately 20 times
more expensive than prostacyclin ($3000/day vs. $150/day) [91]. Table-6 lists the medical
management options, including common doses and common side effects, for intraopera‐
tive management of pulmonary hypertension. Lastly, in patients refractory to the above
therapies, right ventricular assist device implantation should be considered.
Figure 4. Inhaled prostacyclin delivery system Figure-6: Inhaled prostacyclin delivery system. Reconstituted prostacy‐
clin is delivered by a Lo-Flo Mini Heart nebulizer (a), which is driven by a separate oxygen source at 2 L/min (b). The
nebulizer output is 8 mL/h, which allows for 1–3 h of continuous nebulization. The nebulizer should be supported by
an IV pole or ventilator side arm to prevent spillage. An IV port (c) allows the chamber to be refilled without discon‐
necting from the anesthetic circuit. Prostacyclin is photosensitive and requires the nebulizing chamber to be covered
from ambient light (d) [88].
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5. Intravenous prostacyclin (if inhaled is not available) is 4–10 ng/kg/min. In the U.S., iloprost
is inhaled specifically using the I-Neb AAD or Prodose AAD delivery systems. Ventavis
is supplied in 1 mL single-use glass ampules containing either 10 mcg/mL or 20 mcg/mL.
The 20 mcg/mL concentration is intended for patients who are maintained at the 5 mcg
dose and who have repeatedly experienced extended treatment times which could result
in incomplete dosing. Transitioning patients to the 20 mcg/mL concentration using the I-
neb AAD System will decrease treatment times to help maintain patient compliance. The
approved dosing regimen for iloprost is 6 to 9 times daily (no more than every 2 hours)
during waking hours, according to individual need and tolerability.
6. Systemic hypotension should be treated according to the potential causes. Phenylephrine
and norepinephrine have been used to treat persistent systemic hypotension. Norepi‐
nephrine has the advantage of being both a vasoconstrictor and positive inotropic agent.
Vasopressin has also been advocated for treatment of hypotension [68] [92]
7. Sildenafil produced significant pulmonary vasodilatory effect relative to placebo in
anesthetized cardiac surgical patients with pulmonary hypertension. With respect to the
predominant selectivity of sildenafil to pulmonary vasculature shown in this study and
other potentially beneficial effects such as myocardial protection, use of sildenafil in the
intraoperative period in cardiac surgical patients with pulmonary hypertension should
be considered [93]. Sildenafil citrate (INN sildenafil) is a selective phosphodiesterase type
5 inhibitor that is being increasingly recognized as a treatment modality for pulmonary
hypertension.
8. Calcium channel blockers have been shown to inhibit the contraction of pulmonary artery
smooth muscle cells, reduce right ventricular hypertrophy and improve long-term
hemodynamics in PH in a small subset of patients who also show an acute hemodynamic
response to calcium channel blockers. An interesting study demonstrated that survival
was greatly improved in patients who showed a long-term response to calcium channel
blockers; however, in patients that failed on long-term calcium channel blocker therapy,
the 5-year survival rate was only 48% [94]. Calcium channel blockers are now only
recommended for patients with a positive response during acute vasoreactivity testing
and who show sustained hemodynamic improvement [94]. Calcium channel blockers are
the only systemic antihypertensive drugs that have been shown to benefit patients with
PH. By blocking calcium entry into cells of the pulmonary arterial vasculature, calcium
channel blockers can induce vasodilation (or at least prevent vasoconstriction) of pulmo‐
nary arteries. In an initial trial in patients who demonstrated a response to calcium channel
blockers during acute testing, use of calcium channel blockers led to a significant reduction
in mPAP and PVR after 24 hours of treatment. Continued use over 1 year was associated
with improvements in symptoms [94].
Non-pharmacological management of pulmonary hypertension is listed in Table-7.
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6.4. General anesthesia
Without any doubt, every effort should be made to have a smooth induction of anesthesia and
endotracheal intubation which will minimize the hemodynamic instability in highly suscep‐
tible patients. Commonly used intravenous anesthetics such as propofol and thiopental are
associated with hypotension and myocardial depression. Their use should be very judicious.
Etomidate has much fewer effects on SVR, PVR and myocardial contractility and may be a
more useful hypnotic for patient with severe PH. Use of volatile anesthetics is associated with
decreased SVR, myocardial contractility and potential arrhythmias, all of which can impair
right ventricular myocardial perfusion and also right ventricular cardiac output. A balanced
technique utilizing high dose narcotics to blunt the sympathetically mediated cardiovascular
response to surgical stimulation and minimal volatile anesthetics can limit these adverse
effects. Additionally, the anesthesiologist should strive to use basic physiology to her/his
advantage. These principles include utilization of 100% oxygen for its pulmonary vasodilator
Drug category Drug name Delivery pathway/dose Common side effects
Prostaglandins Epoprostenol
(Tradename:Flolan)
Inhaled 31mcg/kg/min Occupational health concern
Iloprost (Ventavis) Inhaled, 6-9 times/day Dizziness, headache, flushing,
lighheatedness,
Treprostinil (Tyvaso) Inhaled, follow doctor's
instraction
Cough, headache, throat
irritation, pain, flushing
Nitric oxide Inhaled nitric oxide Inhaled, 20-50ppm Methemoglobinemia, Lung
toxicity,
Phosphodiesterase
Type-5 inhibitors
Milrinone Intravenous, 50mcg/kg loading,
0.25-0.75 mcg/kg/min
maintenance
Ventricular dysrhythmia,
tachycardia,
Sildenafil Oral, 50 mg preoperatively hypotension
Endothelin receptor
antagonist
Anbrisentan (Letairis in
USA, Volibris in EU)
Bosentan(Tracleer)
2.5-10mg/day, oral Birth defects
62.5mg twice daily, oral for 4
weeks
Hepatotoxicity
Birth defects
Anemia
Nitrovasodilator Nitroglycerin Intravenous, 0.5 g/kg/min, Hypotension, headache
Calcium channel blockers Diltiazem High oral dose:720mg/day Constipation, dizziness,
flushing, headache
Constipation, cough, flushing,
giddiness
Nifedipine Oral 240mg/day
(Copyright owned by Henry Liu, MD)
Table 6. Pharmacological treatment for pulmonary hypertension [94] [95] [96] [97].
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effects, and aggressive treatment of hypercarbia, acidosis, and hypothermia as these may cause
pulmonary vasoconstriction. Certain anesthetic agents such as nitrous oxide and ketamine
have been associated with increases in PVR and should be used with caution [98] [99].
Uncompensated vasodilatation or myocardial depression induced by anesthetics and me‐
chanical ventilation may be responsible for acute RV dysfunction associated with low systemic
blood pressure. Cardiovascular collapse can develop after institution of one-lung ventilation
and pulmonary artery clamping during thoracotomy. An acute increase in pulmonary
pressure results in a decrease in RV ejection fraction and then acute RV failure. Interdepend‐
ence of the right and left ventricles occurs such that RV function can alter LV function. Early
detection of impending circulatory and/or respiratory deterioration is warranted to prevent
an irreversible decline in cardiac output. Inhaled nitric oxide represents the first choice for
treatment of PH and RV failure associated with systemic hypotension during lung transplan‐
tation. Intraoperative situations requiring CPB must be identified before development of
systemic shock, which represents a late ominous sign of RV failure [61].
The anesthetic goals of intraoperative management include optimizing PAP, RV preload and
avoiding RV ischemia and failure. Intraoperatively, often times there are significant alterations
in all above parameters and appropriate vigilance and monitoring are paramount. Intraoper‐
ative management of the RV can be made on the presence of RV failure and the presence of
systemic hyper- or hypotension. Initially, one should ensure that oxygenation, ventilation, and
acid/base status are optimized. Treatment options for PH include both intravenous and inhaled
agents. Intravenous vasodilators, such as nitroglycerin, sodium nitroprusside, beta blockers,
calcium channel blockers, and certain prostaglandin preparations will cause dilation of both
the pulmonary and systemic vascular beds and can be useful in the setting of PH with systemic
hypertension. The advantages to intravenous preparations are the relative decreased cost,
easier availability of medications, and longer duration of action and ease of administration in
comparison to inhaled agents.
1. Ensure adequate oxygenation; avoid hypercarbia;
2. Avoidance of acidosis;
3. Avoidance of hypothermia;
4. Whatever medication is used to control PH, wean the medication slowly to prevent rebound pulmonary
hypertension;
5. Neuraxial anesthesia, peripheral nerve blockade, and lumbar plexus block can all be used to provide surgical
anesthesia for scheduled procedures. But the loading dose should be slow and adjusted according to patient’s
condition. Epidural anesthesia should be induced slowly. Mixtures of local anesthetics and opioids should be given to
reduce the dose of local anesthetics and hypotension;
6. Avoidance of elevating intrapleural pressure which will potentially be transmitted to increased pulmonary arterial
pressure.
(Copyright by Henry Liu, MD)
Table 7. Non-Pharmacological management of pulmonary hypertension
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6.5. Regional anesthesia
Regional anesthetic techniques, including neuraxial blockade (epidural, spinal anesthesia, or
combined epidural and spinal anesthesia) and peripheral nerve blockade (cervical plexus,
auxillary plexus, sciatic nerve, femoral, etc), have all been successfully used in surgical
procedures in patients with severe pulmonary hypertension [100]. Among the benefits of
regional anesthesia are potential minimization of the stimulation-related (direct laryngoscopy,
endotracheal intubation, etc) sympathetic activation. Even with adequate intravenous
anesthetic induction agents, opioids and neuromuscular blockade, it is difficult to avoid
increases in sympathetic nervous system activity due to laryngoscopy and induction. These
sympathetic responses include tachycardia, systemic hypertension and increased myocardial
oxygen consumption, which could lead to increases in PVR and potential acute right heart
failure. During surgery and general anesthesia, due to various surgery-related (incision,
surgical dissection, blood loss etc) or other surgical environment-related stimulations (hypo‐
thermia, psychological stress etc), the anesthesiologist has to continually balance excessive
sympathetic outflow, increased PVR and potential acute right heart failure on one hand and
excessive depth of anesthesia, low cardiac output, low coronary perfusion and cardiovascular
collapse on the other hand [101]. A healthier patient tolerates these variations well, but the
patient with severe PH has limited reserve to compensate for acute increases in PVR or
decreased coronary perfusion. A peripheral nerve block technique could potentially limit
anesthesia to the specific location of the surgery and avoid the need for the stimulation of
intubation and reduced likelihood of sympathectomy and low blood pressure as one would
achieve with general anesthesia. An important distinction is that a sympathectomy is still
possible when utilizing a regional anesthesia technique such as epidural or spinal anesthesia.
This may lead to arterial and venous dilatation and reduced preload and cardiac output
compromising coronary perfusion. When utilizing neuraxial or peripheral nerve block
techniques, it is important to ensure adequate ventilation and oxygenation to prevent increases
in PVR due to hypoxemia. For example, sedation provided to allow the patient to tolerate
placement of a peripheral nerve block or to tolerate lying on the narrow, stiff operating table
may lead to hypoxemia and hypercarbia secondary to hypoventilation. On the other hand,
lack of adequate sedation can promote anxiety, pain and sympathetic stimulation. Achieving
the delicate balance can be a daunting task for anesthesia providers.
For those patients with PH to undergo minor surgical procedures with only monitored
anesthesia care (MAC), special attention should be paid to provide adequate sedation to
minimize patients’ anxiety, which can be harmful because it may lead to increased sympathetic
outflow as we discussed previously. Over-sedation should be avoided to prevent respiratory
suppression and subsequent hypoventilation and hypoxemia which may induce hypoxic
vasoconstriction and elevated PAP.
6.6. Postoperative management
These patients with moderate to severe PH warrant intensive care monitoring in the postop‐
erative period by experienced critical care personnel. As the analgesic and sympathetic
nervous system effects of opioids, volatile anesthetics, and regional anesthetics disappear, the
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patient can develop sudden worsening of PH and RV ischemia. Thus weaning from the
ventilatory support and endotracheal extubation should be done gradually with close attention
to adequate oxygenation, ventilation and analgesia. Even routine events such as bucking on
the ventilator due to tracheal stimulation, while tolerated by the average patient, can lead to
acute rises in PVR and RV failure in patient with severe PH [78]. Postoperative pain manage‐
ment of patients with PH warrants special attention, because in clinical practice, the most
commonly used analgesic agents are opioids which are potent respiratory depressants also.
Depression of respiratory drive will likely cause hypoventilation which leads to increased
PAP. Thus using multimodal analgesic strategy is critical in minimizing the side effect of
respiratory inhibition by opioids and avoiding hypoventilation-associated increase of PAP.
7. Special populations potentially with pulmonary hypertension
7.1. Pediatrics
Pediatric patients with PH have some unique clinical features comparing with adult PH
patients. Genetic factors seem to play a more important role in the pathogenesis of PH. Chida
et al studied fifty-four patients with IPAH or HPAH whose disease was diagnosed at <16 years
of age. Functional characteristics, hemodynamic parameters, and clinical outcomes were
compared in BMPR2 and ALK1 mutation carriers and noncarriers. Overall 5-year survival for
all patients was 76%. Eighteen BMPR2 mutation carriers and 7 ALK1 mutation carriers were
detected in the 54 patients with childhood IPAH or HPAH. Five-year survival was lower in
BMPR2 mutation carriers than mutation noncarriers (55% vs 90%, hazard ratio 12.54, p =
0.0003). ALK1 mutation carriers also had a tendency to have worse outcome than mutation
noncarriers (5-year survival rate 64%, hazard ratio 5.14, p=0.1205). These indicated that patients
with childhood IPAH or HPAH with BMPR2 mutation have the poorest clinical outcomes.
ALK1 mutation carriers tended to have worse outcomes than mutation non-carriers. It is
important to consider aggressive treatment for BMPR2 or ALK1 mutation carriers [102].
Carmosino et al retrospectively studied 156 children with PH with median age 4.0 years who
underwent anesthesia or sedation for noncardiac surgical procedures or cardiac catheteriza‐
tions from 1999 to 2004. PH etiology was 56% idiopathic (primary), 21% AHD, 14% chronic
lung disease, 4% chronic airway obstruction, and 4% chronic liver disease. Baseline PAP was
subsystemic in 68% patients, systemic in 19%, and suprasystemic in 13%. The anesthetic
techniques were 22% sedation, 58% general inhaled, 20% general IV. Minor complications
occurred in eight patients (5.1% of patients, 3.1% of procedures). Major complications includ‐
ing cardiac arrest and pulmonary hypertensive crisis, occurred in seven patients during cardiac
catheterization procedures (4.5% of patients, 5.0% of cardiac catheterization procedures, 2.7%
of all procedures). There were two deaths associated with pulmonary hypertensive crisis (1.3%
of patients, 0.8% of procedures). Based on their observation, they believe baseline suprasys‐
temic PH was a significant predictor of major complications by multivariate logistic regression
analysis (OR = 8.1, P = 0.02) and complications were not significantly associated with age,
etiology of PH, type of anesthetic, or airway management. Children with suprasystemic PH
have a significant risk of major perioperative complications, including cardiac arrest and
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pulmonary hypertensive crisis [103]. Management of pediatric patients with PH poses unique
challenges to pediatric anesthesiologists: PAC may not be available for many smaller pediatric
patients due to the small sizes of their cardiac chamber and blood vessels. TEE may not be
available to some pediatric patients due to lack of suitable size of TEE probe. So transthoracic
or epicardial echocardiography will play a much more important role for those pediatric
patients without TEE and PAC. Minimally invasive/non-invasive monitoring of MAP, CO/CI,
SVV may play some role intraoperatively, however these current technologies may not work
as well in children as in adults [104]. And information from randomized controlled clinical
studies on the treatment of pediatric PH is currently very limited, unanimous opinions are to
refer to the guidelines and treatment strategies for the treatment of adult PH. Therefore, the
recommended treatment for children is only grade IIa with the level of evidence class C.
7.2. Obstetrics
Curry et al reported two maternal deaths out of 12 pregnancies in 9 patients. One of the two
deaths was related to pre-eclampsia and the other related to cardiac arrhythmia. Maternal
morbidity included postpartum hemorrhage (five cases), and one post-caesarean evacuation
of a wound hematoma. There were no perinatal death, nine live births and three first-trimester
miscarriages. Mean birthweight was 2197 grams, mean gestational age was 34 weeks (range
26-39), and mean birthweight percentile was 36 (range 5-60). Five babies required admission
to the neonatal intensive care unit, but were all eventually discharged home. All women were
delivered by caesarean section (seven elective and two emergency deliveries), under general
anesthesia except for one emergency and one elective caesarean performed under regional
block [105]. Maternal and fetal outcomes for women with PH has improved; however, the risk
of maternal mortality remains significant, so that early and effective counseling about
contraceptive options and pregnancy risks should continue to play a major role in the man‐
agement of such women when they reach reproductive maturity.
8. Summary
We have gained better understanding of PH and have significantly more sophisticated
management strategies now compared with two decades ago. PH can develop due to pulmo‐
nary vascular remodeling (cellular proliferation), abnormal vasoconstriction, mechanical
obstruction (chronic thromboembolic events, interstitial lung diseases) or left-side heart
diseases. Thorough preoperative evaluation is mandatory. A clear understanding of the
etiology of pulmonary hypertension is extremely important to understand how to optimally
manage these patients in the operating room. Echocardiography plays a key role in preliminary
screening, monitoring the progress and evolution of PH, and intraoperative monitoring and
treatment. Right heart catheterization remains the gold standard for the diagnosis of PH.
Evaluation of the overall pulmonary functional status is also important in assessing patients'
tolerability to the planned surgical procedure. Perioperatively these patients can present very
challenging clinical scenarios due to the complexity of their PH and increased risks for
significant complications with elevated morbidity and mortality. Several clinical characteris‐
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tics predict early mortality: right axis deviation, right ventricular hypertrophy, RVSP/SBP ratio
above 0.6, and intraoperative use of epinephrine or dopamine. Intraoperative control of
elevated pulmonary pressure can be achieved with inhaled nitric oxide or prostacyclin, PDE
inhibitors (milrinone, sildenafil), calcium channel blockers, nitrodilators and adequate
oxygenation. The ideal perioperative care of these patients requires a multidisciplinary
approach with appropriate planning for pre-procedural optimization, comprehensive
intraoperative monitoring and delicate management of PAP as well as intensive care unit
monitoring in the postoperative period. This approach will test the expertise and resources of
medical institutions. Anesthesiologists will require a thorough understanding of the current
treatment options, pathophysiology of the disease, and the implications of various anesthetic
agents and techniques to provide the highest level of patient safety and care to the patients
with PH.
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